Ecallantide for the treatment of acute attacks in hereditary angioedema.
暂无分享,去创建一个
A. Sheffer | M. Cicardi | M. Campion | W. Pullman | R. Levy | H. Li | P. Horn | D. McNeil
[1] J. Bernstein,et al. Current and Emerging Management Options for Hereditary Angioedema in the US , 2012, Drugs.
[2] C. Thompson,et al. FDA approves kallikrein inhibitor to treat hereditary angioedema. , 2010, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[3] K. Traynor. New drug and biological product approvals, 2009. , 2010, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[4] A. Bygum,et al. Hereditary angio‐oedema in Denmark: a nationwide survey , 2009, The British journal of dermatology.
[5] K. Wyrwich,et al. Psychometric validation of two patient-reported outcome measures to assess symptom severity and changes in symptoms in hereditary angioedema , 2009, Quality of Life Research.
[6] A. Lehmann. Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery , 2008 .
[7] A. Davis. Hereditary angioedema: a current state-of-the-art review, III: mechanisms of hereditary angioedema. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[8] A. Sheffer,et al. Hereditary angioedema: Safety of long-term stanozolol therapy. , 2007, The Journal of allergy and clinical immunology.
[9] Lynda Schneider,et al. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. , 2007, The Journal of allergy and clinical immunology.
[10] J. Levy,et al. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema , 2006, Expert opinion on investigational drugs.
[11] K. Traynor. New drug and biologic product approvals, 2005. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[12] M. López-Trascasa,et al. Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. , 2005, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[13] M. Gompels,et al. C1 inhibitor deficiency: consensus document , 2005, Clinical and experimental immunology.
[14] R. Ladner,et al. Obtaining a family of high-affinity, high-specificity protein inhibitors of plasmin and plasma kallikrein , 1996, Molecular Diversity.
[15] K. Bork,et al. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. , 2003, Archives of internal medicine.
[16] M. Walport,et al. C1q and systemic lupus erythematosus. , 1998, Immunobiology.
[17] R. Ladner,et al. Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin. , 1996, Biochemistry.
[18] A. Davis,et al. Hereditary angioneurotic oedema: characterization of plasma kinin and vascular permeability‐enhancing activities , 1994, Clinical and experimental immunology.
[19] M. Cicardi,et al. Hereditary and Acquired C1‐Inhibitor Deficiency: Biological and Clinical Characteristics in 235 Patients , 1992, Medicine.
[20] A. Kaplan,et al. Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of "spontaneous" formation of bradykinin. , 1983, The Journal of allergy and clinical immunology.
[21] K.,et al. Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation. , 1973, The Journal of clinical investigation.
[22] R. Colman,et al. Interaction of plasma kallikrein with the C1 inhibitor. , 1970, Journal of immunology.